How is Prostate cancer diagnosed?

['Lalela lelikhasi']

Sifo semdlavuza wendlala yemtimba sibonwa njani?

Umdlavuza we-Prostate utfolakala ngekutsi kuhlolwe tintfo letinyenti, letifaka ekhatsi:

1. Kuhlolwa kwe-Digital Rectal (DRE): Dokotela ufaka umuno logcobiswe ngemafutsa futsi logcobiswe ngemaglavu endvwangwini kute abone kutsi kute yini lokungahambi kahle.

2. Prostate-Specific Antigen (PSA) Test: Loku luhlolo lwengati lolukala lizinga le-PSA, iphrotheni lekhicitwa yindlala ye-prostate.

Emazinga laphakeme e-PSA angakhombisa kutsi unemdlavuza we-prostate.

3. Transrectal Ultrasound (TRUS): Kufakwa intfo lencane emphumulweni kute kutfolakale sitfombe salendlala.

Loku kungakusita ubone kutsi kukhona yini lokungahambi kahle kulelicandza.

4. Kuhlolwa kwesitfo semtimba (biopsy): Kutsatfwa sikhumba lesincane se-prostate bese sihlolwa ngemicroscope kute kubonakale kutsi kute yini tinhlayiya temdlavuza.

Lena ngiyo kuphela indlela lecinisekile yekutfola kutsi umuntfu unemdlavuza we-prostate.

5. Magnetic Resonance Imaging (MRI): Kuhlolwa kwe-MRI kungasita kutsi kutfolakale kutsi umuntfu unesifo lesitsite yini, futsi kungamsita kutsi atfole kutsi yini lokufanele ayente.

6. Kuhlolwa kwe-Genome: Labanye bodokotela bangasebentisa luhlolo lwe-genome kute babone kutsi lomdlavuza ungaba nemandla kangakanani futsi basite ekutsatseni tincumo tekwelapha.

7. Kuhlolwa kwematsambo: Kuhlolwa kwematsambo kungentiwa kute kubonwe kutsi umdlavuza sewandzile yini ematsanjeni.

8. I-Computed Tomography (CT) Scan: I-CT scan ingasetjentiswa kute kubonakale kutsi lomdlavuza sewandze na kuletinye titfo temtimba nobe ematsanjeni.

Kubalulekile kwati kutsi akusibo bonkhe labadvuna labanemazinga laphakeme e-PSA nobe imiphumela ye-DRE lengakavami labanawo umdlavuza wendlala yesinye, futsi akusibo bonkhe bomdlavuza wendlala yesinye labangaba nemazinga laphakeme e-PSA.

Ngako-ke, kudzingeka kutsi kutsatfwe sidvumbu kute kutfolakale kutsi lomuntfu unesifo lesitsite.

Ngetulu kwaloko, sincumo sekwenta luhlolo lwekuhlola sidvumbu semuntfu siyentiwa ngemuva kwekuhlola imiphumela yaloluhlolo kanye netintfo letingabangela kugula kanye naloko umuntfu lakutsandzako.

['Tintfo letibhalwe phansi']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM: Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011, 21 (2): 195-205.

Marenco J, Kasivisvanathan V, Emberton M: New standards in prostate biopsy. Arch Esp Urol. 2019, 72 (2): 142-149.

Moradi M, Mousavi P, Abolmaesumi P: Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. Ultrasound Med Biol. 2007, 33 (7): 1010-28.

Cuperlovic-Culf M, Belacel N, Davey M, Ouellette RJ: Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation. Biomarkers. 2010, 15 (8): 693-706.

McGrath SE, Michael A, Morgan R, Pandha H: EN2: a novel prostate cancer biomarker. Biomark Med. 2013, 7 (6): 893-901.

An Y, Chang W, Wang W, Wu H, Pu K, Wu A, Qin Z, Tao Y, Yue Z, Wang P, Wang Z: A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res. 2020, 24 (): 363-370.

[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients]. Zhonghua Wai Ke Za Zhi. 2018, 56 (2): 91-94.

Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chin Med J (Engl). 2006, 119 (7): 570-3.

['Sitatimende: setekwelapha']

['Lelikhasi langcondvomshini liniketelwe kufundzisa nekwatisa kuphela futsi alitsatsi seluleko setekwelapha nobe umsebenti wetingcweti.']

['Lemininingwane leniketwako akukafaneli isetjentiselwe kutfola nobe kwelapha tinkinga temphilo nobe tifo, futsi labo labafuna lusito lwetekwelapha kufanele batsintse dokotela lonemvume yekwenta njalo.']

['Uyacelwa kutsi ucaphele kutsi luhlelo lwekuchumana lolwakha timphendvulo temibuto, alukabi kahle kakhulu uma kukhulunywa ngetinombolo. Sibonelo, sibalo sebantfu labanesifo lesitsite.']

['Ngaso sonkhe sikhatsi cela seluleko kudokotela wakho nobe lomunye loniketa lusito lwetemphilo mayelana nesimo sakho sekugula. Ungalokotsi unganaki seluleko sebucwepheshe nobe wephute kusitfola ngenca yalokutsite lokufundze kulewebhusayithi. Uma ucabanga kutsi kungenteka unekugula, shayela 911 nobe uye egunjini lelisedvute lekuphutfuma ngekushesha. Kute budlelwane emkhatsini wetekwelapha nesigulane lobentiwa ngulewebhusayithi nobe kusetjentiswa kwayo. I-BioMedLib nobe basebenti bayo, nobe ngumuphi umuntfu lofaka sandla kulewebhusayithi, akenti nobe nguyiphi imiculu, lechazako nobe lechazako, mayelana nemniningwane loniketwe lapha nobe kusetjentiswa kwayo.']

['Liciniso: copyright']

['Umtsetfo we-Digital Millennium Copyright Act wanga-1998, 17 U.S.C. § 512 (i-DMCA) uniketa indlela yekusitwa kubanikati bemalungelo ekushicilela labakholelwa kutsi tintfo letivela ku-Internet tiphula emalungelo abo ngaphansi kwemtsetfo we-U.S. wekushicilela. ']

['Nangabe ukholelwa kutsi nobe nguyiphi intfo nobe intfo lekhona kulewebhusayithi nobe etinhlelweni tetfu yephula emalungelo akho, wena (nobe ummeli wakho) ungasitfumelela satiso ucele kutsi leyo nto nobe intfo isuswe nobe ivinjelwe.']

['Tatiso kumele titfunyelwe nge-email (buka likheli le-email kusigaba "Sekuchumana").']

['I-DMCA idzinga kutsi satiso sakho sekuhlukumeta emalungelo eluntfu sicukatse lemininingwane lelandzelako: (1) inchazelo yemsebenti logunyatwe emalungelo eluntfu lokutsiwa uphasiwe; (2) inchazelo yalokucuketfwe lokutsiwa kuphasiwe kanye nemininingwane leyenele kutsi sikhone kutfola lokucuketfwe; (3) imininingwane yekutsintsana nawe, kufaka ekhatsi likheli lakho, inombolo yelucingo nelikheli le-email; (4) sitatimende sakho sekutsi unenkolelo lenhle yekutsi lokucuketfwe ngendlela lokhonjiwe akukavumeleki kumnikati wemalungelo eluntfu, nobe kummeli wakhe, nobe ngekusebenta kwanoma ngumuphi umtsetfo; ']

['(5) sitatimende sakho, lesisayinwe ngaphasi kwesijeziso sekufunga emanga, sekutsi umniningwane lokuso satiso ucinisile nekutsi uneligunya lekuvikela emalungelo e-copyright lasolwa kutsi ephuliwe;']

['kanye (6) nekusayina ngekwemtimba nobe nge-elekthroniki kwemnikati we-copyright nobe umuntfu logunyatiwe kutsi ente umsebenti egameni lemnikati we-copyright. ']

['Kwehluleka kufaka yonkhe lemininingwane lengenhla kungaholela ekubambelekeni kwekusetjentwa kwesikhalo sakho.']

['Kuchumana']

['Sicela usitfumelele i-email nganobe nguwuphi umbuto / umbono.']

How is prostate cancer diagnosed?

Prostate cancer is diagnosed through a combination of tests and procedures, which may include:

1. Digital Rectal Exam (DRE): A doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for any abnormalities.

2. Prostate-Specific Antigen (PSA) Test: This is a blood test that measures the level of PSA, a protein produced by the prostate gland.

Elevated PSA levels may indicate the presence of prostate cancer.

3. Transrectal Ultrasound (TRUS): A small probe is inserted into the rectum to create an image of the prostate using sound waves.

This can help identify any abnormalities in the prostate gland.

4. Biopsy: A small sample of prostate tissue is removed and examined under a microscope for the presence of cancer cells.

This is the only definitive way to diagnose prostate cancer.

5. Magnetic Resonance Imaging (MRI): An MRI scan of the prostate can help identify any abnormalities and guide the biopsy procedure.

6. Genomic Testing: Some doctors may use genomic tests to help determine the aggressiveness of the cancer and guide treatment decisions.

7. Bone Scan: A bone scan may be performed to check if the cancer has spread to the bones.

8. Computed Tomography (CT) Scan: A CT scan may be used to check if the cancer has spread to other organs or tissues.

It is important to note that not all men with elevated PSA levels or abnormal DRE results will have prostate cancer, and not all prostate cancers will cause elevated PSA levels.

Therefore, a biopsy is necessary to confirm the diagnosis.

Additionally, the decision to undergo a biopsy is made after considering the results of these tests and the individual's risk factors and preferences.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.